EU Approves Illumina’s Plan to Divest Cancer Diagnostic Test Maker Grail

U.S. gene sequencing company Illumina’s plan to divest cancer diagnostic test maker Grail has received the green light from EU antitrust regulators which blocked the deal two years ago.

Illumina jumped the gun in 2021 when it completed the $7.1-billion acquisition before first securing EU regulatory approval.

That prompted the European Commission, which acts as the competition enforcer in the 27-country European Union, to order the company to keep Grail separate from Illumina.

Read the source article at Yahoo Finance